This significant increase in response rates and median survival times has been observed in melanoma and RCC, leading to the approval of the ipilimumab (anti-CTLA-4 mAb) and nivolumab (anti-PD-1 mAb) combination for the treatment of these cancers (98, 99). Here, CTLA4 is linked to melanoma.